Investigating the expression profiles of KMT2D in AML patients, we found that compared to normal control (CD34+ cord blood samples, n = 17), AML samples (n = 43) contained significantly lower KMT2D expression (GSE48173[28]). The gene discussed is CD34; the disease is acute myeloid leukemia.